Biogen (BIIB) delivered a notable turnaround this year, posting EPS growth of 32.1% after five years of average annual declines of 20.5%. Net profit margins improved to 15.3% from last year’s 12%.

Garg, recently named to BioSpace’s 40 Under 40, proved her mettle managing one of the toughest partnerships out there: the ...

Discover Biogen's Q3 2025 earnings: 67% launch product growth, strategic pipeline expansion, and updated guidance amid evolving market dynamics.

Biogen Inc. ( BIIB) Q3 2025 Earnings Call October 30, 2025 8:30 AM EDT Good morning. My name is Cynthia, and I will be your conference operator today. At this time, I would like to welcome everyone to ...

A new drug-sales king has been crowned. Eli Lilly’s diabetes and weight-loss drug tirzepatide, marketed under the Mounjaro ...

Alnylam and Neurocrine shares tumbled despite upbeat sales reports. Elsewhere, Biogen is dealing with what one analyst called ...

Two of Biogen's key growth drivers hit snags in the third-quarter. But Biogen stock yo-yoed and, most recently, edged down ...

Biogen beat Wall Street estimates for third-quarter profit, helped by better-than-expected sales of some of its multiple ...

As momentum for Biogen’s newer drugs for neurological disorders builds at a slow and steady pace, it appears that the company ...

Biogen cut its full-year adjusted-earnings expectations, though third-quarter profit rose on strength from its Alzheimer’s ...

Biogen Inc. cut its full-year profit guidance on higher costs from deals the company has been doing to offset the decline of ...